Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 29
  1. Apr 23, 2026 · 16:16 · SVA · Routine +

    Sernova Biotherapeutics

    Sernova Biotherapeutics Announces Closing of Recently Approved Financings

    01
  2. Apr 23, 2026 · 12:45 · EYE · Routine +

    Rise Nano Optics Confirms FDA Status and First US Lab Partner, Yet Commercialization Scale Remains Unproven

    Market One: Rise Nano Optics Secures First U.S. Lab Partnership as SPECTRAGUARD(TM) Commercialization Advances

    02
  3. Apr 23, 2026 · 08:01 · BPC · Neutral

    Management pivots to commercial spend amid regulatory clarity, but revenue visibility remains absent

    The Precision Peptide Company Announces Strategic Product Marketing Agreement

    03
  4. Apr 23, 2026 · 08:00 · VST · Routine +

    Pawsible Ventures Cohort Launch Validates Victory Square Diversification Strategy as Hydreight Scales

    Pawsible Ventures Unveils First Cohort Targeting the $300B Pet Health Opportunity

    04
  5. Apr 23, 2026 · 08:00 · LOBE · Routine +

    Balance Sheet Restructuring and Regulatory Tailwinds Support Pipeline Progress

    Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders

    05
  6. Apr 23, 2026 · 07:30 · MRVL · Routine +

    Marvel Biosciences Secures Funding and Patent Protection for Phase 1 Neurodevelopmental Candidate MB-204

    Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit

    06
  7. Apr 23, 2026 · 07:00 · BLCO · Routine +

    Bausch + Lomb Executes H1 Roadmap with AREDS3 Launch Amidst Debt Refinancing and Earnings Growth

    Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

    07
  8. Apr 23, 2026 · 07:00 · CNVI · Routine +

    Conavi Medical Awarded 2026 TAG Innovation

    Conavi Medical Awarded 2026 TAG Innovation Award

    08
  9. Apr 22, 2026 · 19:13 · CTX · Routine +

    Crescita Therapeutics Moves Closer to ClinActiv Takeover at $0.80 Premium

    Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings

    09
  10. Apr 22, 2026 · 16:17 · ALZI · Routine +

    Alzai Health Files Final Prospectus for $4M Best-Efforts IPO

    Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering

    10
  11. Apr 22, 2026 · 09:16 · QNTM · Routine +

    Unbuzzd CEO Appointment Signals Commercial Push Amidst MS Pipeline Progress

    Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

    11
  12. Apr 22, 2026 · 08:23 · VVTM · Routine +

    VVT Med Secures First Tranche Financing Amid Regulatory Filing Delays

    VVT Med Closes $1,065,664 First Tranche of Private Placement of Units

    12
  13. Apr 22, 2026 · 07:15 · BLCO · Routine +

    Sustainability Report Confirms Long-Term ESG Goals

    Bausch + Lomb Releases 2025 Sustainability Impact Report

    13
  14. Apr 22, 2026 · 07:00 · EPRX · Routine +

    Eupraxia Confirms Durable Efficacy and Safety Profile Ahead of Phase 2b Top-Line Readout

    Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

    14
← Newer Older →